Chapter 8

Anti-Ricin Protective Monoclonal Antibodies

Wei-Gang Hu, Junfei Yin, Damon Chau, Charles C. Hu and John W. Cherwonogrodzky

Abstract

Development of anti-ricin protective monoclonal antibodies (mAbs) started in the early 1980s. Much progress has been made since then. Antibodies possess great potential for development as antidotes against toxins. These can be used either prophylactically to prevent, or therapeutically to treat, toxin-mediated intoxications in an emergency situation. Unlike many other therapeutic products, antibodies offer unique and high target specificity, and long half-life in serum. There are several mAbs which are currently in the discovery stage for medical countermeasures against ricin intoxication. This review summarizes these mAbs, including their anti-ricin mechanism, generation, and efficacies in vivo.

Total Pages: 145-158 (14)

Download Free  Book Details

RELATED BOOKS

.Endocannabinoids: Molecular, Pharmacological, Behavioral and Clinical Features.
.Frontiers in Clinical Drug Research- HIV.
.Frontiers in Clinical Drug Research-Anti-Infectives.
.Endocannabinoids: Molecular, Pharmacological, Behavioral and Clinical Features.
.Solubility, Delivery and ADME Problems of Drugs and Drug-Candidates.
.
            The Pharmaceutical Scientist Guide to Solution Kinetic Models Mathematical Description and Applications.